Prediction of individual treatment response to biologics by ex-vivo immunological testing in rheumatoid arthritis
Recruiting
- Conditions
- chronic arthritisRArheumatoid arthritis10023213
- Registration Number
- NL-OMON41052
- Lead Sponsor
- Sint Maartenskliniek
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 400
Inclusion Criteria
• Rheumatoid arthritis (either 2010 ACR RA and/or 1987 RA criteria and/or clinical diagnosis of the treating rheumatologist, fulfilled at any time point between start of the disease and inclusion)
• Patients with RA who start with (or switch to) a biologic (including abatacept, adalimumab, etanercept, rituximab and tocilizumab)
• Concomitant treatment with conventional DMARDs and/or NSAIDs is permitted
• Age >= 18 years
• Informed consent
• Ability to measure the study outcome in the patient (e.g. life expectancy >6 months, no planned relocation far away)
• Ability to read and communicate well in Dutch
Exclusion Criteria
None
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method